Beyond the Surface: Tailored Solutions for Tear Evaporation in Meibomian Gland Dysfunction : Episode 6
Differentiating Between the Semi-Fluorinated Alkane-Based Therapies for Dry Eye
Selina McGee, OD, FAAO, discusses the role of cyclosporine ophthalmic solution (VEVYE) in the treatment of dry eye disease.
EP: 1.Overview of MGD and Its Causes
EP: 2.Differentiating Aqueous vs Evaporative Dry Eye
EP: 3.Long-Term Consequences of Untreated MGD
EP: 4.Factors to Consider in Treatment Selection for MGD
EP: 5.Managing Evaporative Dry Eye with New FDA-Approved Therapy
Now Viewing
EP: 6.Differentiating Between the Semi-Fluorinated Alkane-Based Therapies for Dry Eye
EP: 7.Combining In-Office and At-Home Therapies
EP: 8.Clinical Case Scenario: Management Strategies for MGD and Key Takeaways
Video content above is prompted by the following questions:
- When do you prefer to use cyclosporine ophthalmic solution, 0.1% (VEVYE)? How are the indications for this drug different from perfluorohexyloctane ophthalmic solution?
Recent Videos
Related Content
